In recent years， traditional Chinese medicine （TCM） has achieved significant progress in the treatment of inflammatory bowel disease （IBD）. A comprehensive literature search was conducted covering the period from January 1， 2010， to December 30， 2024， across Chinese databases including China National Knowledge Infrastructure （CNKI）， Wanfang Data， VIP China Science and Technology Journal Database， and the Chinese Biomedical Literature Service System， as well as international databases such as PubMed， Web of Science， and Embase. The clinical applications and mechanistic studies of TCM in IBD were systematically reviewed. The current status of TCM research on the etiology and pathogenesis of IBD， innovative clinical practices， and multimodal therapeutic approaches， including Chinese herbal formulas， single herbs or active compounds， acupuncture， herbal retention enema， and acupoint application， were summarized， together with their synergistic effects when combined with western medical treatments. The development and application of Chinese patent medicines for IBD are undergoing a profound transition from efficacy validation to mechanistic exploration. Mechanistic studies on the effects of TCM in IBD mainly focus on regulating gut microbiota homeostasis， repairing the intestinal mucosal barrier， and modulating intestinal immune balance. Furthermore， future research directions for TCM-based IBD management are proposed， including the establishment of TCM diagnostic and treatment models， expanding integrated applications of external and internal TCM therapies， innovating personalized treatment strategies， and advancing drug development. These efforts aim to provide insights for the standardized and precision-oriented development of TCM in the diagnosis and treatment of IBD.

Animal model research on spleen and stomach diseases in traditional Chinese medicine （TCM） is of great significance for elucidating the nature of diseases and syndromes and for revealing the mechanisms of action of Chinese herbal medicinals. At present， studies on classical TCM syndrome models of spleen and stomach diseases mainly focus on spleen deficiency syndrome， liver constraint syndrome， and damp-heat syndrome. Model construction is mostly based on the etiological and pathophysiological characteristics of syndrome， and model evaluation primarily involves macroscopic manifestations and physicochemical indicators. This paper summarizes the current research status of animal models integrating disease and syndrome for seven common spleen and stomach diseases， including chronic gastritis and gastric precancerous lesions， gastroesophageal reflux disease， functional dyspepsia， inflammatory bowel disease， irritable bowel syndrome， functional constipation， and functional diarrhea. The modeling methods and characteristics of disease-syndrome combined animal models for each disease are analyzed. It is proposed that future research on disease-syndrome integration in spleen and stomach diseases should move toward syste-matic， precise， and integrative development， and that interdisciplinary and cross-disciplinary research approaches should be adopted to enhance the predictive value and application efficiency of disease-syndrome combined animal models.

Aligning with the ulcerative colitis （UC） dynamic characteristics of latent pathogens， that is "remaining latent and concealed， and manifesting when triggered"， and following the latent pathogen theory， it is proposed that the core pathogenesis of UC recurrence is latent damp-heat pathogen concealed internally， progressing from qi to blood level over time， and leading to qi-blood disharmony and intestinal collateral damage. Accordingly， stage-based treatment is recommended. During the active stage， it is suggested to clear damp-heat， move qi， and regulate blood using modified Gegen Qinlian Decoction（葛根芩连汤）. During the remission stage， the treatment should focus on reinforcing healthy qi and venting pathogen， regulate and tonify the spleen and kidney with a self-made Jianpi Qingchang Mixture（健脾清肠合剂）. These approaches may provide a reference for the clinical treatment of UC.

Schizophrenia is a chronic and debilitating mental disorder.Around 20%to 40%of patients do not respond well to normal antipsychotic medication,and are ultimately diagnosed with treatment-resistant schizophrenia(TRS),representing the most severe and challenging form of schizophrenia.Currently,clozapine is the standard treatment for TRS.Early identification and standardized treatment can be beneficial to patients with TRS by controlling acute-phase symptoms as soon as possible,reducing suicidal rate and improving their quality of life.Under the guidance of the Steering Committee,this consensus was formed after multiple discussions by 30 psychiatric experts and anonymous Delphi surveys including 17 consensus opinions on treatment-resistant schizophrenia,which cover risk factors and prevention,diagnosis and evaluation,standardized clozapine treatment and management of adverse reactions,treatment regimens for clozapine resistance and intolerance,and psychosocial intervention,etc.The consensus-making process also incorporated evidence-based medicine to help standardize and guide diagnosis and treatment for adults with TRS in China.

Objective:To explore the efficacy of unilateral biportal endoscopic (UBE) decompression combined with percutaneous pedicle screw fixation in the treatment of thoracolumbar burst fracture.Methods:A retrospective series study was conducted on the clinical data of 26 patients with thoracolumbar burst fracture who were admitted to Second Affiliated Hospital, University of South China between January 2023 and June 2024, including 18 males and 8 females, aged 14-58 years [(37.2±12.7)years]. Fractured segments included T 12 in 2 patients, L 1 in 3, L 2 in 9, L 3 in 7, and L 4 in 5. According to the American Spinal Injury Association (ASIA) scale, 2 patients were classified as grade C and 24 as grade D. All the patients were treated with UBE decompression combined with percutaneous pedicle screw fixation. The anterior vertebral height ratio (AVHR), vertebral wedge angle (VWA), kyphosis Cobb angle (KCA), vertebral compression efficiency ratio (VCER), visual analogue scale (VAS) and ASIA grade were compared preoperatively, at 3 days postoperatively and at the last follow-up. Postoperative complications were observed. Results:All the patients were followed up for 6-12 months [(8.7±1.9)months]. At 3 days postoperatively and at the last follow-up, AVHR [(93.7±2.2)%, (88.8±2.5)%], VWA [(3.9±1.2)°, (4.4±1.3)°] and KCA [(5.4±1.4)°, (6.1±1.4)°] were significantly improved compared with those preoperatively [(76.7±3.1)%, (7.0±2.9)°, (12.3±3.4)°, respectively] ( P<0.05). At the last follow-up, AVHR was decreased but VWA and KCA were increased in comparison with those at 3 days postoperatively ( P<0.05). VCER was (18.5±6.9)% at 3 days postoperatively and (18.1±6.4)% at the last follow-up, which were improved in comparison with that preoperatively [(53.6±7.7)%] ( P<0.05). There was no significant difference in VCER at the last follow-up and at 3 days postoperatively ( P>0.05). The VAS score was decreased from (8.5±0.7)points preoperatively to (3.5±0.7)points at 3 days postoperatively and further to (1.0±0.8)points at the last follow-up ( P<0.05), and there was statistically significant difference between the VAS scores at 3 days postoperatively and at the last follow-up ( P<0.05). At the last follow-up, 2 patients with ASIA grade C recovered to grade D, while 24 patients with ASIA grade D recovered to grade E ( P<0.01). Asymptomatic epidural hematoma was found in 1 patient and drainage tube-related limb pain in 1, but no instances of incision infection, cerebrospinal fluid leakage, decreased muscle strength, loosening or breakage of internal fixation were observed in other patients. Conclusion:The combined application of UBE decompression and percutaneous pedicle screw fixation demonstrates significant clinical advantages in treating thoracolumbar burst fractures, including fracture reduction of the injured vertebra, spinal canal decompression, thoracolumbar back pain relief, neurological function recovery and lower complication rates.

Objective:To investigate the efficacy of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE)combined with Apatinib Mesylate and Camrelizumab in the treatment of older patients with hepatocellular carcinoma and portal vein tumor thrombus(PVTT).Methods:A total of 80 older patients with hepatocellular carcinoma and PVTT, admitted to the Second People's Hospital of Pinghu City from January 2020 to December 2023, were selected as the study subjects.Among them, 40 patients receiving DEB-TACE combined with Apatinib Mesylate and Camrelizumab constituted the experimental group, while the other 40 patients receiving Apatinib Mesylate combined with Camrelizumab formed the control group.The response evaluation criteria in solid tumors(RECIST)were employed to assess the clinical efficacy of both groups.Overall survival(OS)and progression-free survival(PFS)were compared, and univariate and multivariate Cox regression analyses were used to analyze the influencing factors of OS in patients.Results:The objective response rate(ORR)and disease control rate(DCR)of the experimental group were significantly higher than those of the control group[60.0%(24/40) vs.32.5%(13/40), 80.0%(32/40) vs.50.0%(20/40), χ2=6.085, 0.013, P=0.013, 0.004]. The median OS and PFS of the experimental group were significantly greater than those of the control group(18.3 months vs.12.2 months, Log-rank χ2=6.470, P=0.011; 8.2 months vs.5.7 months, Log-rank χ2=11.106, P=0.001). Multivariate Cox proportional regression analysis indicated that ALBI grade( HR=1.356, 95% CI: 1.159-1.588, P=0.006), extrhepatic metastasis( HR=1.133, 95% CI: 1.015-1.265, P=0.009), and DEB-TACE( HR=1.921, 95% CI: 1.293-2.854, P=0.001)were independent prognostic factors in older patients with hepatocellular carcinoma and PVTT. Conclusions:The combination of DEB-TACE, Apatinib Mesylate, and Camrelizumab in the treatment of older patients with hepatocellular carcinoma and PVTT can significantly enhance clinical efficacy and extend patient survival.

In recent decades,the incidence of human papillomavirus(HPV)-associated oropharyngeal squamous cell carcinoma(OPSCC)has shown a marked increase.Significant changes have also occurred in the OPSCC diagnosis and treatment paradigm.Deter-mining HPV status prior to treatment is now essential,and radiotherapy/chemotherapy,immunotherapy,and minimally invasive surgical techniques have progressively emerged as key modalities for managing OPSCC.However,alongside these paradigm shifts,a comprehen-sive technical consensus guiding the entire diagnostic and therapeutic process for OPSCC patients is currently lacking.Given China's large population base and the rising incidence of OPSCC,an expert panel convened to develop a clinical technical consensus on OPSCC diagno-sis and management tailored to China's specific context.This consensus aims to further enhance and standardize understanding of OPSCC management techniques among relevant healthcare professionals.

Objective:To explore the efficacy of unilateral biportal endoscopic (UBE) decompression combined with percutaneous pedicle screw fixation in the treatment of thoracolumbar burst fracture.Methods:A retrospective series study was conducted on the clinical data of 26 patients with thoracolumbar burst fracture who were admitted to Second Affiliated Hospital, University of South China between January 2023 and June 2024, including 18 males and 8 females, aged 14-58 years [(37.2±12.7)years]. Fractured segments included T 12 in 2 patients, L 1 in 3, L 2 in 9, L 3 in 7, and L 4 in 5. According to the American Spinal Injury Association (ASIA) scale, 2 patients were classified as grade C and 24 as grade D. All the patients were treated with UBE decompression combined with percutaneous pedicle screw fixation. The anterior vertebral height ratio (AVHR), vertebral wedge angle (VWA), kyphosis Cobb angle (KCA), vertebral compression efficiency ratio (VCER), visual analogue scale (VAS) and ASIA grade were compared preoperatively, at 3 days postoperatively and at the last follow-up. Postoperative complications were observed. Results:All the patients were followed up for 6-12 months [(8.7±1.9)months]. At 3 days postoperatively and at the last follow-up, AVHR [(93.7±2.2)%, (88.8±2.5)%], VWA [(3.9±1.2)°, (4.4±1.3)°] and KCA [(5.4±1.4)°, (6.1±1.4)°] were significantly improved compared with those preoperatively [(76.7±3.1)%, (7.0±2.9)°, (12.3±3.4)°, respectively] ( P<0.05). At the last follow-up, AVHR was decreased but VWA and KCA were increased in comparison with those at 3 days postoperatively ( P<0.05). VCER was (18.5±6.9)% at 3 days postoperatively and (18.1±6.4)% at the last follow-up, which were improved in comparison with that preoperatively [(53.6±7.7)%] ( P<0.05). There was no significant difference in VCER at the last follow-up and at 3 days postoperatively ( P>0.05). The VAS score was decreased from (8.5±0.7)points preoperatively to (3.5±0.7)points at 3 days postoperatively and further to (1.0±0.8)points at the last follow-up ( P<0.05), and there was statistically significant difference between the VAS scores at 3 days postoperatively and at the last follow-up ( P<0.05). At the last follow-up, 2 patients with ASIA grade C recovered to grade D, while 24 patients with ASIA grade D recovered to grade E ( P<0.01). Asymptomatic epidural hematoma was found in 1 patient and drainage tube-related limb pain in 1, but no instances of incision infection, cerebrospinal fluid leakage, decreased muscle strength, loosening or breakage of internal fixation were observed in other patients. Conclusion:The combined application of UBE decompression and percutaneous pedicle screw fixation demonstrates significant clinical advantages in treating thoracolumbar burst fractures, including fracture reduction of the injured vertebra, spinal canal decompression, thoracolumbar back pain relief, neurological function recovery and lower complication rates.

Objective:To investigate the efficacy of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE)combined with Apatinib Mesylate and Camrelizumab in the treatment of older patients with hepatocellular carcinoma and portal vein tumor thrombus(PVTT).Methods:A total of 80 older patients with hepatocellular carcinoma and PVTT, admitted to the Second People's Hospital of Pinghu City from January 2020 to December 2023, were selected as the study subjects.Among them, 40 patients receiving DEB-TACE combined with Apatinib Mesylate and Camrelizumab constituted the experimental group, while the other 40 patients receiving Apatinib Mesylate combined with Camrelizumab formed the control group.The response evaluation criteria in solid tumors(RECIST)were employed to assess the clinical efficacy of both groups.Overall survival(OS)and progression-free survival(PFS)were compared, and univariate and multivariate Cox regression analyses were used to analyze the influencing factors of OS in patients.Results:The objective response rate(ORR)and disease control rate(DCR)of the experimental group were significantly higher than those of the control group[60.0%(24/40) vs.32.5%(13/40), 80.0%(32/40) vs.50.0%(20/40), χ2=6.085, 0.013, P=0.013, 0.004]. The median OS and PFS of the experimental group were significantly greater than those of the control group(18.3 months vs.12.2 months, Log-rank χ2=6.470, P=0.011; 8.2 months vs.5.7 months, Log-rank χ2=11.106, P=0.001). Multivariate Cox proportional regression analysis indicated that ALBI grade( HR=1.356, 95% CI: 1.159-1.588, P=0.006), extrhepatic metastasis( HR=1.133, 95% CI: 1.015-1.265, P=0.009), and DEB-TACE( HR=1.921, 95% CI: 1.293-2.854, P=0.001)were independent prognostic factors in older patients with hepatocellular carcinoma and PVTT. Conclusions:The combination of DEB-TACE, Apatinib Mesylate, and Camrelizumab in the treatment of older patients with hepatocellular carcinoma and PVTT can significantly enhance clinical efficacy and extend patient survival.

Objective To analyze the research status,hotspots,and trends of wearable devices in nursing applications both domestically and internationally.Methods Using China National Knowledge Infrastructure,Wanfang Data Knowledge Service Platform,and Embase core databases as data sources,VOSviewer was used to visualize and analyze the publication time,keywords,and other relevant literature.Results Total of 428 articles were included,including 196 Chinese articles and 232 English articles.The overall publication volume showed an upward trend.Domestic research focuses on chronic diseases,artificial intelligence,and nursing,with the main research subjects being the elderly;Foreign research focuses on smart devices,self-monitoring,and quality of life,with the main research subjects being adults.Conclusion Currently,the number of publications on the application of wearable devices in nursing is relatively small,but the overall research heat is on the rise,mainly used for chronic diseases and self-monitoring.In the future,the application scope of wearable devices should be expanded and their potential value should be explored to promote the innovation and progress of nursing models.